Cipla is in collaboration with MEDA in the field of allergic rhinitis. Cipla and Meda will build further on the existing collaboration by granting global commercialization rights to Meda for Dymista, excluding some markets for which Cipla will take the commercial lead.
With the same agreement, both companies will collaborate on follow-up compounds for Dymista, capitalising on intellectual property retained by both partners. This agreement is part of a broader relationship between the two companies in the field of allergic rhinitis.
Commenting on the extended agreement, Subhanu Saxena, Global Chief Executive Officer, Cipla said, “We are pleased to announce the new agreement with Meda, who is our strategic partner in the area of Allergic Rhinitis.
Dymista nasal spray approved by US FDA, is a new patented product for the treatment of seasonal allergic rhinitis (SAR) in patients 12 years of age and older who require treatment with both azelastine hydrochloride and fluticasone proprionate for symptomatic relief.
EP News Bureau – Mumbai